



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

FEBRUARY 22, 2018

PTAS

COOLEY LLP
ATTN: IP DOCKETING DEPARTMENT
1299 PENNSYLVANIA AVENUE, NW, SUITE
700
WASHINGTON, DC 20004

504787233

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 02/21/2018

REEL/FRAME: 044991/0771
NUMBER OF PAGES: 9

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: JETH-001/02WO 327130-2008

ASSIGNOR:

STAFFORD, JEFFREY A.

DOC DATE: 02/20/2018

ASSIGNOR:

VEAL, JAMES M.

DOC DATE: 02/20/2018

ASSIGNOR:

TRZOSS, LYNNIE LIN

DOC DATE: 02/20/2018

ASSIGNOR:

MCBRIDE, CHRISTOPHER

DOC DATE: 02/20/2018

ASSIGNEE:

JECURE THERAPEUTICS, INC.
4757 NEXUS CENTER DRIVE
SUITE 150
SAN DIEGO, CALIFORNIA 92121

APPLICATION NUMBER:

FILING DATE: 01/22/2018

PATENT NUMBER:

ISSUE DATE:

PCT NUMBER: US2018014728

TITLE: CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY

ASSIGNMENT RECORDATION BRANCH

PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4833965

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JEFFREY A. STAFFORD	02/20/2018
JAMES M. VEAL	02/20/2018
LYNNIE LIN TRZOSS	02/20/2018
CHRISTOPHER MCBRIDE	02/20/2018
RECEIVING PARTY DATA	
Name:	JECURE THERAPEUTICS, INC.
Street Address:	4757 NEXUS CENTER DRIVE
Internal Address:	SUITE 150
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 1	
Property Type	Number
PCT Number:	US2018014728
CORRESPONDENCE DATA	
Fax Number:	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(650) 843-5694
Email:	zPatDCDocketing@cooley.com, kcheung@cooley.com
Correspondent Name:	COOLEY LLP
Address Line 1:	ATTN: IP DOCKETING DEPARTMENT
Address Line 2:	1299 PENNSYLVANIA AVENUE, NW, SUITE 700
Address Line 4:	WASHINGTON, D.C. 20004
ATTORNEY DOCKET NUMBER:	JETH-001/02WO 327130-2008
NAME OF SUBMITTER:	CONNIE C. TONG
SIGNATURE:	/Connie C. Tong/
DATE SIGNED:	02/21/2018
Total Attachments: 7	

ASSIGNMENT

Lynnie Lin
TRZOSS

Inventor
initials dl
Date 2/21/18

Jeffrey A. STAFFORD, residing at 12752 Sandy Crest Court, San Diego, CA 92130; **James M. VEAL**, residing at 8916 Weaver Crossing Road, Apex, NC 27502; ~~**Lonnie Lin TRZOSS**~~, residing at 9120 Meadowrun Way, San Diego, CA 92129; and **Christopher MCBRIDE**, residing at 10595 Montego Drive, San Diego, CA 92124 (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent entitled **CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY**, and which is a:

Country	Application No.	Application Date
Argentina	20180100141	January 22, 2018
International Application (PCT)	PCT/US2018/014728	January 22, 2018
Taiwan	107102246	January 22, 2018

WHEREAS, JECURE THERAPEUTICS, INC., a having its principal place of business at 4757 Nexus Center Drive, Suite 150, San Diego, CA 92121, its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent identified above;
- (c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the

Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;

(d) any application(s) for patent of the United States or other countries claiming the Invention(s);

(e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any priority application(s), substitute application(s), division(s), continuation(s), and continuation(s)-in-part;

(f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and

(g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

Attorney Docket No. JETH-001/02WO/TW/AR 308043-2008/2009/2010

The Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified above when known.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Feb 20, 2018
Date

Jeffrey A. Stafford
Jeffrey A. STAFFORD

WITNESSED BY: Kim Russell
DATE: 2/20/18
NAME: Kim Russell

2/20/2018
Date

James M. VEAL
James M. VEAL

WITNESSED BY: Kim Russell
DATE: 2/20/18
NAME: Kim Russell

2/20/18
Date

Lin TRZOSS
~~Lonnie~~ LYNNIE

WITNESSED BY:

DATE:

NAME:


Kim Russell

2/20/18

Kim Russell

2-20-18


Date



Christopher MCBRIDE

WITNESSED BY:


DATE: 2/20/18
NAME: Kim Russell

For and on behalf of ASSIGNEE

Date: Feb 20, 2018 By: 
Name: Jeffrey A. Stafford
Title: CEO
Company: JECURE THERAPEUTICS, INC.

WITNESSED BY: 
DATE: 2/20/18
NAME: Kim Russell